It is a fully human IgG1/kappa monoclonal antibody that blocks TIGIT/CD155 binding, and it was used in combination with atezolizumab (anti-PD-L1 mAb) in recurrent or metastatic NSCLC. The gene discussed is PVR; the disease is non-small cell lung carcinoma.